Telehealth model versus in-person standard care for persons with type 1 diabetes treated with multiple daily injections: an open-label randomized controlled trial

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Ballesta, Silvia
• dc.contributor.author Chillarón Jordan, Juan José
• dc.contributor.author Inglada, Yolanda
• dc.contributor.author Climent Biescas, Elisenda
• dc.contributor.author Llauradó Cabot, Gemma
• dc.contributor.author Pedro-Botet, Juan Carlos
• dc.contributor.author Cots, Francesc
• dc.contributor.author Camell, Helena
• dc.contributor.author Flores, Juana Antonia
• dc.contributor.author Benaiges Foix, David
• dc.date.accessioned 2024-03-19T07:32:29Z
• dc.date.available 2024-03-19T07:32:29Z
• dc.date.issued 2023
• dc.description.abstract Objective: Increasing evidence indicates that the telehealth (TH) model is noninferior to the in-person approach regarding metabolic control in type 1 diabetes (T1D) and offers advantages such as a decrease in travel time and increased accessibility for shorter/frequent visits. The primary aim of this study was to compare the change in glycated hemoglobin (HbA1c) at 6 months in T1D care in a rural area between TH and in-person visits. Research design and methods: Randomized controlled, open-label, parallel-arm study among adults with T1D. Participants were submitted to in-person visits at baseline and at months 3 and 6 (conventional group) or teleconsultation in months 1 to 4 plus 2 in-person visits (baseline and 6 months) (TH group). Mixed effects models estimated differences in HbA1c changes. Results: Fifty-five participants were included (29 conventional/26 TH). No significant differences in HbA1c between groups were found. Significant improvement in time in range (5.40, 95% confidence interval (CI): 0.43-10.38; p < 0.05) and in time above range (-6.34, 95% CI: -12.13- -0.55;p < 0.05) in the TH group and an improvement in the Diabetes Quality of Life questionnaire (EsDQoL) score (-7.65, 95% CI: -14.67 - -0.63; p < 0.05) were observed. In TH, the costs for the participants were lower. Conclusions: The TH model is comparable to in-person visits regarding HbA1c levels at the 6-month follow-up, with significant improvement in some glucose metrics and health-related quality of life. Further studies are necessary to evaluate a more efficient timing of the TH visits.
• dc.format.mimetype application/pdf
• dc.identifier.citation Ballesta S, Chillarón JJ, Inglada Y, Climent E, Llauradó G, Pedro-Botet J, et al. Telehealth model versus in-person standard care for persons with type 1 diabetes treated with multiple daily injections: an open-label randomized controlled trial. Front Endocrinol (Lausanne). 2023 Jun 27;14:1176765. DOI: 10.3389/fendo.2023.1176765
• dc.identifier.doi http://dx.doi.org/10.3389/fendo.2023.1176765
• dc.identifier.issn 1664-2392
• dc.identifier.uri http://hdl.handle.net/10230/59476
• dc.language.iso eng
• dc.publisher Frontiers
• dc.relation.ispartof Front Endocrinol (Lausanne). 2023 Jun 27;14:1176765
• dc.rights © 2023 Ballesta, Chillarón, Inglada, Climent, Llauradó, Pedro-Botet, Cots, Camell, Flores and Benaiges. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Chronic complications
• dc.subject.keyword Emerging technologies
• dc.subject.keyword Metabolic control
• dc.subject.keyword Telehealth
• dc.subject.keyword Type 1 diabetes
• dc.title Telehealth model versus in-person standard care for persons with type 1 diabetes treated with multiple daily injections: an open-label randomized controlled trial
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion